560
Views
70
CrossRef citations to date
0
Altmetric
Drug Profile

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

, &
Pages 151-158 | Published online: 10 Jan 2014
 

Abstract

Inhibition of the platelet ADP P2Y12 receptor has shown to be associated with a marked risk reduction of atherothrombotic events in high-risk settings, including patients with acute coronary syndromes and those undergoing percutaneous coronary interventions. Clinical and laboratory experiences have led to a better comprehension of the drawbacks of currently available P2Y12 receptor antagonists, stimulating the development of novel agents. Ticagrelor (AZD6140) is the first drug of a new chemical class called cyclopentyltriazolopyrimidine, which is administered orally and has a reversible P2Y12 receptor inhibitory effect. Preclinical and early-phase clinical studies have shown ticagrelor to be characterized by a rapid, greater and consistent antiplatelet effect with a favorable safety profile. Recent findings from large-scale Phase III trials showed ticagrelor to be more effective in preventing ischemic events in acute coronary syndrome patients without an increased risk of protocol-defined major bleeding, but with an increase in the rate of nonprocedure-related bleeding, compared with currently recommended treatment regimens. This article provides an overview of the pharmacologic properties and clinical development of ticagrelor.

Financial & competing interests disclosure

Dominick J Angiolillo receives honoraria from and provides lectures to Bristol Myers Squibb, Sanofi-aventis, Eli Lilly and Company, and Daiichi Sankyo, Inc. He is also on the advisory board at Bristol Myers Squibb, Sanofi-aventis, Eli Lilly and Company, Daiichi Sankyo, Inc., AstraZeneca, The Medicines Company, Portola Pharmaceuticals, Novartis and Arena Pharmaceuticals. In addition, Dominick J Angiolillo has received research grants from GlaxoSmithKline, Otsuka, Accumetrics, Eli Lilly and Company, Daiichi Sankyo, Inc., The Medicines Company, AstraZeneca, Eisai, Portola Pharmaceuticals, Schering-Plough, and Johnson and Johnson. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 611.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.